source
- Akeso details survival win for its PD-1xVEGF drug versus KeytrudaAkeso and Summit Therapeutics claimed a key win over Keytruda at the start of September, and are now spelling out that survival data. They hope it will add to the trove of results supporting the ...Endpoints · 27m ago↗ source
- Novartis encounters setbacks while AI firm Anthropic searches for a dealmakerThe latest Endpoints Weekly edition highlights a difficult period for Novartis, noting that the company is facing a series of setbacks. Details of the challenges are not provided, but the report s…
- Yarrow Bioscience raises $150M as AbbVie reports positive menstrual migraine trial results